title: Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer.
abstract: OBJECTIVE
  Primary subglottic cancer is a rare malignancy. We investigated the efficacy and toxicity of radiotherapy for subglottic cancer.
  
  
  METHODS
  Nineteen patients with primary squamous cell carcinoma of the subglottis received radiotherapy, 14 of whom also underwent chemotherapy. Of the 19 patients, 15 received definitive radiotherapy to the gross tumors with total doses of 70-70.2 Gy in 35-39 fractions, and 4 underwent preoperative radiotherapy with total doses of 37.8-55.8 Gy in 21-31 fractions, followed by total laryngectomy.
  
  
  RESULTS
  Of the 19 patients, 5 developed local progression and 2 developed distant metastasis at the median follow-up period of 5 years. The 5-year local control and disease-free rates were 74 and 63%, respectively. Three patients died of tumor progression, and the 5-year overall and disease-free survival rates were 80 and 63%, respectively. Regarding acute toxicities, transient mucositis and dermatitis of grade 3 or lower were observed in all patients, but there were no late toxicities of grade 3 or higher.
  
  
  CONCLUSIONS
  Radiotherapy is a safe and effective treatment for patients with primary squamous cell carcinoma of the subglottis. The use of chemotherapy together with radiotherapy may enhance treatment efficacy and contribute to larynx preservation through good local control.
authors.affiliation: Department of Radiology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, 236-0004, Yokohama, Japan. mhata@syd.odn.ne.jp
authors.forename: M
authors.initials: M
authors.lastname: Hata
authors.forename: T
authors.initials: T
authors.lastname: Taguchi
authors.forename: I
authors.initials: I
authors.lastname: Koike
authors.forename: G
authors.initials: G
authors.lastname: Nishimura
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Komatsu
authors.forename: D
authors.initials: D
authors.lastname: Sano
authors.forename: K
authors.initials: K
authors.lastname: Odagiri
authors.forename: Y
authors.initials: Y
authors.lastname: Minagawa
authors.forename: T
authors.initials: T
authors.lastname: Inoue
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018450:Disease Progression; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D007825:Laryngectomy; D007830:Larynx / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology*; D011879:Radiotherapy Dosage; D016896:Treatment Outcome